BIEL 2026 and 2027 Revenue Projections (per AI) for Three Scenarios - Status Quo, Moderate Partnership and Full Integration:
Status Quo Scenario
2026 Revenue: $2M
Product sales only (pain patches, electroceutical devices).
Limited distribution, no major reimbursement adoption.
2027 Revenue: $3M
Small organic growth from niche adoption.
Margins remain thin, operating losses continue.
Moderate Partnership Scenario
2026 Revenue: $15M
Licensing/IP fees from Electrome or similar partner.
Initial ACCESS reimbursement adoption in select hospitals/clinics.
Mix of product sales + royalties.
2027 Revenue: $20M
Expanded reimbursement coverage across more states.
Stronger partner distribution channels.
Net profit margin 15% ($3M profit).
Full Integration Scenario
2026 Revenue: $30M
National-scale rollout with Electrome integration.
Reimbursement codes fully active, enabling insurance-backed adoption.
Revenue mix: 70% licensing/IP, 30% product sales.
2027 Revenue: $50M
Rapid scaling through AI-driven therapy adoption.
ACCESS program fully leveraged for nationwide reimbursement.
Net profit margin 25% ($12M profit).
Key Takeaways
Status Quo: <$3M revenue, ongoing losses.
Moderate Partnership: $15M–$20M revenue, breakeven to modest profit.
Full Integration: $30M–$50M revenue, strong profitability by 2027.
Drivers: FDA readiness, ACCESS reimbursement, Electrome synergy, leaner cost structure.
Risks: Partnership not confirmed, regulatory delays, execution challenges.
Why is the profit margin only 15 - 25%?
Key Reasons for Margin Limits
Healthcare Distribution Costs
Even with licensing/IP revenue, partners like Electrome will spend heavily on marketing, physician outreach, and reimbursement navigation.
BIEL’s share of revenue will be diluted by these distribution and commercialization costs.
Reimbursement Administration
ACCESS program adoption requires compliance, reporting, and outcome tracking.
These administrative layers reduce net margins compared to pure software/IP businesses.
Licensing Economics
Licensing deals typically yield royalty rates of 10–20% of partner revenue.
Even if Electrome scales nationally, BIEL’s cut is capped by contract terms.
Ongoing R&D & Regulatory Costs
FDA filings, clinical trials, and compliance are recurring expenses.
Downsizing offices reduces overhead, but regulatory/IP backbone operations still carry fixed costs.
Healthcare Industry Norms
Medical device and therapy companies often operate at 15–25% net margins once scaled.
Higher margins (30–40%) are rare unless the company controls full distribution and manufacturing, which BIEL is moving away from.
Margin Breakdown by Scenario
Status Quo: Margins negative due to small scale and fixed costs.
Moderate Partnership: 15% net margin - reflects licensing + partial reimbursement adoption.
Full Integration: 25% net margin - reflects national rollout, strong reimbursement, but still capped by healthcare economics.
Summary
Margins are constrained by licensing royalty structures, healthcare compliance costs, and distribution economics.
The upside is that BIEL avoids manufacturing risk, so margins improve compared to its current losses.
15–25% is realistic for a healthcare IP/licensing backbone — profitable, but not software-level margins.
Status Quo Scenario
2026 Revenue: $2M
Product sales only (pain patches, electroceutical devices).
Limited distribution, no major reimbursement adoption.
2027 Revenue: $3M
Small organic growth from niche adoption.
Margins remain thin, operating losses continue.
Moderate Partnership Scenario
2026 Revenue: $15M
Licensing/IP fees from Electrome or similar partner.
Initial ACCESS reimbursement adoption in select hospitals/clinics.
Mix of product sales + royalties.
2027 Revenue: $20M
Expanded reimbursement coverage across more states.
Stronger partner distribution channels.
Net profit margin 15% ($3M profit).
Full Integration Scenario
2026 Revenue: $30M
National-scale rollout with Electrome integration.
Reimbursement codes fully active, enabling insurance-backed adoption.
Revenue mix: 70% licensing/IP, 30% product sales.
2027 Revenue: $50M
Rapid scaling through AI-driven therapy adoption.
ACCESS program fully leveraged for nationwide reimbursement.
Net profit margin 25% ($12M profit).
Key Takeaways
Status Quo: <$3M revenue, ongoing losses.
Moderate Partnership: $15M–$20M revenue, breakeven to modest profit.
Full Integration: $30M–$50M revenue, strong profitability by 2027.
Drivers: FDA readiness, ACCESS reimbursement, Electrome synergy, leaner cost structure.
Risks: Partnership not confirmed, regulatory delays, execution challenges.
Why is the profit margin only 15 - 25%?
Key Reasons for Margin Limits
Healthcare Distribution Costs
Even with licensing/IP revenue, partners like Electrome will spend heavily on marketing, physician outreach, and reimbursement navigation.
BIEL’s share of revenue will be diluted by these distribution and commercialization costs.
Reimbursement Administration
ACCESS program adoption requires compliance, reporting, and outcome tracking.
These administrative layers reduce net margins compared to pure software/IP businesses.
Licensing Economics
Licensing deals typically yield royalty rates of 10–20% of partner revenue.
Even if Electrome scales nationally, BIEL’s cut is capped by contract terms.
Ongoing R&D & Regulatory Costs
FDA filings, clinical trials, and compliance are recurring expenses.
Downsizing offices reduces overhead, but regulatory/IP backbone operations still carry fixed costs.
Healthcare Industry Norms
Medical device and therapy companies often operate at 15–25% net margins once scaled.
Higher margins (30–40%) are rare unless the company controls full distribution and manufacturing, which BIEL is moving away from.
Margin Breakdown by Scenario
Status Quo: Margins negative due to small scale and fixed costs.
Moderate Partnership: 15% net margin - reflects licensing + partial reimbursement adoption.
Full Integration: 25% net margin - reflects national rollout, strong reimbursement, but still capped by healthcare economics.
Summary
Margins are constrained by licensing royalty structures, healthcare compliance costs, and distribution economics.
The upside is that BIEL avoids manufacturing risk, so margins improve compared to its current losses.
15–25% is realistic for a healthcare IP/licensing backbone — profitable, but not software-level margins.
3
